BioHealth News Archive
GSK puts up to $815M on the table for Surface Oncology’s antibody | FierceBiotech
GlaxoSmithKline is stumping up $85 million upfront and up to an extra $730 million in biobucks for Surface Oncology’s early-stage antibody asset. The drug…
Read More
Weller Development’s Port Covington project gets boost as $137.5 million in bonds hit market – Baltimore Business Journal
Work on the $5.5 billion project has been at a standstill since April due to the Covid-19 pandemic. Image: Work on the $5.5 billion…
Read More
5 Questions with Brian Darmody, CEO, Association of University Research Parks · BioBuzz
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little…
Read More
MacKenzie Scott Donates Tens of Millions to Maryland HBCUs – NBC4 Washington
Philanthropist and author MacKenzie Scott is donating tens of millions of dollars to historically black universities in Maryland. The Baltimore Sun reported Tuesday that…
Read More
Funding Opportunities | MSCRF – 1/14 Deadling to Apply
We offer six programs to accelerate discovery and commercialization of human stem cell-based technologies. Please verify eligibility, read the appropriate RFA below and apply here. Companies…
Read More
Liquid Biopsy Predicts Esophageal Cancer Patient Response to Treatment | Business Wire
ROCKVILLE, Md.--(BUSINESS WIRE)--Creatv MicroTech, a privately-held biotechnology company has pioneered a blood test to predict treatment response in patients with newly diagnosed Stage I-III…
Read More
COVID-19 Strategic Renewal Task Force Report | ConnnectedDMV
COVID-19 STRATEGIC RENEWAL TASK FORCE REPORT {iframe}https://www.connecteddmv.org/taskforce-report{/iframe}
Read More
REGENXBIO Announces Positive Interim Data and Update for Phase I/II Trial of RGX-121 for the Treatment of MPS II | BioSpace
ROCKVILLE, Md., Dec. 8, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of…
Read More
Novavax Appoints Vaccine Industry Expert Margaret G. McGlynn to Board of Directors | Novavax Inc. – IR Site
GAITHERSBURG, Md., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today…
Read More
Vaccitech, Future Planet backed Oxford Spinout, Offers Global Path to End of COVID-19 — Future Planet Capital
This week, interim Phase III data was released for the Oxford / AstraZeneca Vaccine, co-invented by our portfolio company Vaccitech. From late December, assuming…
Read More
Novo Holdings: the world’s largest biotech investor | Sifted
What’s the world’s largest charitable foundation? Nope, its not the Bill and Melinda Gates Foundation. Not even the Wellcome Trust. It’s Novo Nordisk Foundation,…
Read More
AUTM 2021 Conference
Top Reasons to Attend: The world may have stopped, but your professional development doesn't have to. Education and networking from the comfort of your…
Read More2020: The Human Immunome: Small Moves Become a Movement — The Golden Goose Award
The Human Immunome: Small Moves Become a Movement “We’re basic scientists. We did not set out initially just to make drugs. That’s not what…
Read More
COVID-19 — The Disease That Is Reshaping Manufacturing | NIST
Unless you’ve been living on private island (send invite immediately!), it’s no secret that the pandemic has changed the way manufacturers operate and run…
Read More
Avoid these 5 real-world data pitfalls when planning your patient registry, cohort study, or observational clinical study
When clinical investigators and study coordinators start planning a new study design, speed and efficiency are paramount. Running a clinical study takes careful planning.…
Read More